Is the beauty sector still attractive?
While beauty, cosmetics and skincare firms bet big on China, a tougher market threatens their premium valuations


Beauty has been a popular sector among investors who like high-quality companies. These brands were seen as relatively defensive: even in a recession, customers were likely to keep buying their favourite products as an affordable luxury. And there was good potential for growth since customers in emerging markets would buy more cosmetics and high-end skincare from desirable foreign brands as they became wealthier. So a slump last week in the shares of Japan’s Shiseido and South Korea’s Amorepacific is worth noting.
Shiseido is off almost 24% after disappointing results that showed continued weak demand in China. As a one-off, this might not be a complete shock: the company had also reported weak full-year results for 2023 driven by China and had already announced plans to cut costs and improve profitability. Its shares peaked in 2019 and have been looking weak since mid-2023. However, Amorepacific fell a similar amount after earnings missed expectations, with continued weak demand in China. Looking back further, US group Estée Lauder had a dire 2023 on the back of problems… yes, China. So all this is starting to look like a bit of a worrying pattern.
Is investing in the beauty sector worth it?
It seems clear that the market that once offered the greatest promise for global beauty – and provided much of the justification for why these firms should trade on elevated valuations – is becoming very challenging. There are two likely factors. First, underlying growth and consumer demand in China continue to be weak. Second, consumers may be turning more towards local brands for reasons that range from value for money to nationalism or domestic pride.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shiseido says that controversy over the release of treated water from the Fukushima nuclear power plant is affecting demand for Japanese products (misinformation about this is widespread in China). Such risks are not new. When South Korea agreed in 2016 to allow a US missile defence system to be deployed in the country, there were government-backed campaigns to boycott South Korean products. Amorepacific’s share price has never regained the bubbly peak it hit back then and, like, Shiseido has been on a wobbly downtrend for a while.
Earnings forecasts for the beauty sector imply a decent rebound even for the underperformers in 2025. Yet in China, competition from local brands is likely to get tougher. Rules that will force cosmetics firms to disclose the precise composition of their products to regulators have raised concerns about whether this could mean trade secrets get leaked. And the China risks put a lot of weight on the US and Europe to be steady and other emerging markets to show growth. Most firms now trade on price/earnings ratios in the 20-25 range based on estimates for 2025. There are some excellent stocks in this sector: I still hold L’Oréal in my multinationals portfolio, alongside diversified groups such as Procter & Gamble and Unilever. But as with other consumer stories that have recently disappointed, there is a risk that valuations come down across the board.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
Review: Trasierra – a yoga retreat in the Spanish hills
Flora Connell joins a yoga retreat at Trasierra, in the Sierra Morena mountains north of Seville
By Flora Connell Published
-
How much should I have in emergency savings?
When your boiler breaks or your car won’t start, you can find yourself paying a hefty bill. How much should you have in emergency savings to cover unexpected costs?
By Katie Williams Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published